(3-(2-Methyl-1H-imidazol-1-yl)phenyl)methanol | 167758-86-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (3-(2-Methyl-1H-imidazol-1-yl)phenyl)methanol
• 英文别名: [3-(2-methylimidazol-1-yl)phenyl]methanol
• CAS: 167758-86-3
• 化学式: C₁₁H₁₂N₂O
• 分子量: 188.23
• InChiKey: KFGVBPICTGIJJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE<br/>[FR] INHIBITEURS DE TRIAZOLOPYRIDINE DE LA MYÉLOPEROXYDASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017040450A1

  公开（公告）日：2017-03-09

  The present invention provides compounds of Formula (I): wherein A, Y and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

  本发明提供了式（I）的化合物：其中A、Y和R1如规范中所定义，并包括任何此类新化合物的组合物。这些化合物是髓过氧化物酶（MPO）抑制剂和/或嗜酸性粒细胞过氧化物酶（EPX）抑制剂，可用作药物。
• Triazolopyridine inhibitors of myeloperoxidase
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10316035B2

  公开（公告）日：2019-06-11

  The present invention provides compounds of Formula (I): wherein A, Y and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

  本发明提供了式(I)化合物：其中A、Y和R1各自如说明书中所定义，以及包含任何此类新型化合物的组合物。这些化合物是髓过氧化物酶（MPO）抑制剂和/或嗜酸性粒细胞过氧化物酶（EPX）抑制剂，可用作药物。
• IMIDAZOLES AS LIPOXYGENASE INHIBITORS
  申请人：PFIZER INC.

  公开号：EP0703913B1

  公开（公告）日：1997-06-11
• IMIDAZOLE LIPOXYGENASE INHIBITORS
  申请人：PFIZER INC.

  公开号：EP0703913A1

  公开（公告）日：1996-04-03
• TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20180244671A1

  公开（公告）日：2018-08-30

  The present invention provides compounds of Formula (I): wherein A, Y and R 1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.